Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2003-07-08
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 6000
- Registration Number
- NCT00002582
- Locations
- 🇬🇧
Cancer Research Campaign Trials Unit-Birmingham (CRCTU), Birmingham, England, United Kingdom
🇬🇧Beatson Oncology Centre, Glasgow, Scotland, United Kingdom
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
- Conditions
- Prostate Cancer
- Interventions
- Procedure: conventional surgeryRadiation: radiation therapy
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 413
- Registration Number
- NCT00055731
- Locations
- 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷Hopital Saint Andre, Bordeaux, France
🇫🇷Institut Bergonie, Bordeaux, France
Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2014-12-16
- Lead Sponsor
- UNICANCER
- Registration Number
- NCT00053911
- Locations
- 🇫🇷
Clinique Claude Bernard, Albi, France
🇫🇷Institut Bergonie, Bordeaux, France
🇫🇷Centre Paul Papin, Angers, France
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2022-12-30
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 983
- Registration Number
- NCT00004124
- Locations
- 🇺🇸
Cancer Care Center at Advocate Lutheran Hospital, Park Ridge, Illinois, United States
🇺🇸Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸Bismarck Cancer Center, Bismarck, North Dakota, United States
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Procedure: orchiectomyRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 361
- Registration Number
- NCT00002633
- Locations
- 🇨🇦
QEII Health Sciences Center, Halifax, Nova Scotia, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 1386
- Registration Number
- NCT00003653
- Locations
- 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇨🇦BCCA - Fraser Valley Cancer Centre, Surrey, British Columbia, Canada
🇨🇦Clinical Research Unit at Vancouver Coastal, Vancouver, British Columbia, Canada
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 41
- Registration Number
- NCT00028769
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸CCOP - Central Illinois, Decatur, Illinois, United States
Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 150
- Registration Number
- NCT00031850
- Locations
- 🇬🇧
Christie Hospital NHS Trust, Manchester, England, United Kingdom
Combination Chemotherapy in Treating Women With Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 446
- Registration Number
- NCT00047099
- Locations
- 🇩🇪
Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich, Germany
🇩🇪I. Frauenklinik und Hebammenschule der Ludwig-Maximillians Universitaet Muenchen, Munich, Germany
Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 110
- Registration Number
- NCT00014586
- Locations
- 🇩🇪
Center of Operative Urology Bremen, Bremen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.